RecruitingNot Applicable

Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

United States40 participantsStarted 2024-10-10

Plain-language summary

The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use. The main objectives are to: * Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury * To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program. Participants will: * Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit * Complete Treatment Effectiveness Assessments at 6 and 12-weeks * Engage in a qualitative interview at the end of the CM program

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Admitted trauma patients * Age greater than 18 years old * Urine drug screen positive for methamphetamines during the current hospitalization * Report at least weekly methamphetamine use * First methamphetamine use greater than 6 months prior to injury * Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease) * Glasgow Coma Scale ≥13 upon arrival to the emergency department * Ability to understand and participate in study procedures * Ability to communicate in English Exclusion Criteria: * Active psychosis (reporting auditory or visual hallucinations) * Under ongoing cardiorespiratory monitoring * Evidence of moderate or severe traumatic brain injury * Patients who are known to be pregnant * Prisoner * Individuals incarcerated at the time of their hospitalization * Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent

What they're measuring

TEA Outcomes at 6 and 12-weeks

Timeframe: From enrollment to 6 and 12-weeks

Trial details

NCT IDNCT06532370

SponsorQueen's Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-30

Contact for this trial

Nicholas R Schumann, Clinical Psychologist

(808) 691-7024 nschumann@queens.org